Forma Therapeutics Holdings Inc. (FMTX): Price and Financial Metrics
FMTX Price/Volume Stats
Current price | $20.01 | 52-week high | $20.68 |
Prev. close | $19.98 | 52-week low | $4.95 |
Day low | $19.98 | Volume | 739,100 |
Day high | $20.01 | Avg. volume | 847,595 |
50-day MA | $16.65 | Dividend yield | N/A |
200-day MA | $10.81 | Market Cap | 957.54M |
FMTX Stock Price Chart Interactive Chart >
Forma Therapeutics Holdings Inc. (FMTX) Company Bio
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.
Latest FMTX News From Around the Web
Below are the latest news stories about FORMA THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate FMTX as an investment opportunity.
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the DiseaseHANOVER, MD and WATERTOWN, Mass., September 30, 2022--Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease |
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreRegulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week. |
Novo Nordisk (NVO) to Tap Into SCD Space With Forma AcquisitionNovo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space. |
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition NewsThere's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news. |
Guardforce AI (GFAI) Stock Gets a Boost From New Exec TeamGuardforce AI (GFAI) stock is climbing higher on Thursday after announcing a new executive team that will lead the company. |
FMTX Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | N/A |
3-year | -18.59% |
5-year | N/A |
YTD | N/A |
2023 | N/A |
2022 | 0.00% |
2021 | -59.26% |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...